Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Brokerages

Immatics N.V. (NASDAQ:IMTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.6667.

Several equities analysts have issued reports on IMTX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Immatics in a research note on Wednesday, October 8th. Guggenheim started coverage on Immatics in a research note on Thursday, September 18th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, Zacks Research raised Immatics from a "strong sell" rating to a "hold" rating in a research note on Monday, October 13th.

Hedge Funds Weigh In On Immatics

Institutional investors have recently added to or reduced their stakes in the business. Trexquant Investment LP acquired a new position in Immatics in the first quarter valued at approximately $783,000. Vontobel Holding Ltd. acquired a new position in shares of Immatics during the second quarter worth approximately $59,000. Pale Fire Capital SE raised its position in shares of Immatics by 8.9% during the first quarter. Pale Fire Capital SE now owns 34,270 shares of the company's stock worth $155,000 after purchasing an additional 2,808 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Immatics by 38.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock worth $66,194,000 after purchasing an additional 4,072,226 shares during the period. Finally, Aberdeen Group plc raised its position in shares of Immatics by 107.1% during the first quarter. Aberdeen Group plc now owns 719,586 shares of the company's stock worth $3,245,000 after purchasing an additional 372,207 shares during the period. 64.41% of the stock is owned by institutional investors and hedge funds.

Immatics Price Performance

Immatics stock opened at $10.18 on Friday. The stock's 50 day moving average is $7.53 and its 200 day moving average is $6.16. The firm has a market cap of $1.24 billion, a P/E ratio of -15.66 and a beta of 1.22. Immatics has a one year low of $3.30 and a one year high of $11.25.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.28). The company had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%. Equities analysts anticipate that Immatics will post -0.72 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.